IRS - Sygehus Lillebælt, Forskningsenhed for Hæmatologi (Vejle)

Medicin og biovidenskab

1. Multiple Myeloma 100%
2. daratumumab 79%
3. Lenalidomide 26%
4. Lymphoma, Large B-Cell, Diffuse 25%
5. Dexamethasone 20%
6. Bortezomib 14%
7. Therapeutics 13%
8. Lymphoma 12%
9. Rituximab 12%
10. Survival 11%
11. Cohort Studies 11%
12. Osteoclasts 10%
13. Progression-Free Survival 10%
14. Bone Marrow 9%
15. B-Cell Chronic Lymphocytic Leukemia 9%
16. Registries 9%
17. Population 8%
18. Bone and Bones 7%
19. Bone Diseases 7%
20. Monoclonal Antibodies 7%
21. Monoclonal Gammopathy of Undetermined Significance 6%
22. Cyclophosphamide 6%
23. Melphalan 6%
24. melflufen 6%
25. Osteoblasts 6%
26. Transplants 6%
27. Safety 5%
28. Stem Cell Transplantation 5%
29. Denmark 5%
30. fludarabine 5%
31. Drug Therapy 5%
32. Bone Remodeling 5%
33. Prednisone 5%
34. Plasma Cells 5%
35. Anthracyclines 5%